This month I started a $500 day trading challenge
It took me 2 days to turn $500 into $1k so I decided to up the ante and change it into a $500 -> $5k challenge
I was expecting it to take me a month to secure x10 gains (900%)
But itβs took me only 6 days to x10 my returns
End of Day 6
$500 -> $5820
1064% profits π’π’π’π’π’
All my alerts were shared live on my account here for free
Now time for us to hit 1k followers π
9 trading days ago, this was supposed to be a simple $500 β $1,000 challenge.
Today the account sits at $11,137 !!! π€―
π+2,127% π
21 trades
15 green
3 red
3 breakeven
6 trades over +50%
This is NOT normal and should not be anyone's expectation.
A lot went right, especially the momentum in Chinese names this week.
I was fortunate to capitalize on it.
What I'm most proud of isn't the P&L
Every alert was posted live on X.
Every trade was transparent.
An absolutely insane run that took countless hours, discipline, and work
Taking tomorrow off and watching the $SPCX madness from the sidelines.
750 followers or 100 likes and we run it back Monday from just $500
$TMDE
This was an oil theme trade
Didnβt get the volume weβd have liked
Exiting all positions here.
$500 day trade account near $11k so donβt want to lose more here
$1.30 -> $1.05
-19% π΄
-$570
$ADIL
Big news: Adial is acquiring Azora Therapeutics and raising up to $64M in new funding
- $32M upfront $32M toed to future milestone
The deal will completely change the company.
After the transaction:
- Existing Adial shareholders will now only own about 7.7% of the combined company after closing and shareholder approval.
- Former Azora holders will own 51.0%.
- New financing investors will own 41.3%.
ADIL now becomes an Azora-focused biotech with significantly more cash to fund development.
The downside is HEAVY DILUTION for current shareholders.
Takeaway:
This is essentially a reset for ADIL. Investors should now focus on Azoraβs pipeline and how the new funding will be used rather than Adialβs previous business.
Swing Trade $ADIL - alert 19 May
1st entry: $2.15 /// 2nd entry: $1.95 dips
Avg price: $2.05 /// SL: $1.80
Due Diligence -
Adial Pharmaceuticals is a low-float biotech developing AD04, a treatment targeting alcohol addiction and substance use disorders
Apr. 9, 2026
$ADIL filed new patents that could protect AD04 from competition until 2045
Apr. 23, 2026
The company said the FDA may allow AD04 to move forward with only one large final trial instead of two, which could save time and money.
May 1, 2026
Adial completed an important manufacturing step needed before starting its next major study.
May 8, 2026
$ADIL announced a European partnership deal that could eventually bring the company up to ~$60M through milestone payments and royalties.
May 15, 2026
The company applied for a special FDA fast-track style program that could help speed up review timelines if approved.
$GLXG
$4.15 -> $4.70 but didnβt sell
Adding dips: $2.60
Size $1k
Avg Entry: $3.75
Total size: $4k
This is just a pure lotto trade for me
Already reached the target $10k
Expecting a bounce back in the afternoon
$GLXG
$4.15 -> $4.70 but didnβt sell
Adding dips: $2.60
Size $1k
Avg Entry: $3.75
Total size: $4k
This is just a pure lotto trade for me
Already reached the target $10k
Expecting a bounce back in the afternoon